research reports and media, page-3077

Mozz I can feel your level of excitment building and I just got a call from Elon about using Space-X for the launch program instead of Cape Canaveral. I told him I would be in touch...
Now not wanting to fire off my own pop gun too early as I have done along time ago but........... As we have fast track(FT) this gives us the ear of the FDA and I expect PAR will be providing them with updates as data comes to hand so I think this gives PAR a good insight into if the FDA thinks an AA would fly. I think you are on the money and sometime shortly after the 002's would be when AA gets granted. This perhaps would allow for 003 to be progressing alongside of the AA and we Licensing approval on or about last patient dosing of 003.

You would have thought other OA drug's would have got a similar FDA pathway todate (given the size of the OA problem) but Im guessing none have really had the Safety profile IPPS has.

Given the increase in the number of Testing centres PAR have engaged (ie Canada) Im wondering (naively) if 002 will progress faster as a result. Based on the R&D Day slides 2020, once all subjects are recruited, the Data Readout is 2 quarters later so an idea of the numbers recruited and speed of recruitment will be telling. Just not sure in relation to 002 how the dosing selection holds up the actual commencement of treatment. They have been pretty coy on dosing for 002, I know they say they are recruiting but have we had a dosing update?

Exciting times.

The Pool